|
Pacific Biosciences of California, Inc. is a life science technology company that designs, develops, and manufactures advanced sequencing solutions. Its core technology is HiFi long-read sequencing based on Single-Molecule Real-Time (SMRT) science, which enables the analysis of genomes, transcriptomes, and epigenomes. The company’s product portfolio includes sequencing instruments such as the Sequel II and Revio systems, nanofluidic chips known as SMRT Cells, and reagents for DNA and RNA sequencing. Key solutions include whole genome sequencing, targeted sequencing, epigenetics, and RNA sequencing, supported by kits like the Kinnex full-length RNA Kit and the PureTarget enrichment platform. Applications span human germline sequencing, oncology, infectious disease and microbiology, and plant and animal sciences. Customers include academic and governmental research institutions, commercial testing laboratories, genome centers, public health labs, hospitals, clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. In January 2026, the company completed the sale of certain short-read DNA sequencing assets to Illumina Cambridge Limited. Summarised from the company's own disclosures, fiscal year ended Feb 2026 |
Industry Medical Devices | Homepage pacb.com |
| Sector Healthcare | IR page investor.pacificbiosciences.com | |
|
Tags
long-read sequencing, genomics, transcriptomics, epigenetics, oncology, infectious disease, plant sciences, animal sciences, rare disease, clinical research, HiFi, SMRT, Sequel II, Revio, SMRT Cells, Kinnex, PureTarget
|
Press page pacb.com/news-events/press-releases |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 970.433M |
| Market cap (USD) | $ 970.433M |
| P/E | -7.77 |
| PEG | — |
| P/BV | -15.81 |
| P/S | 6.01 |
| P/OCF | -7.09 |
| P/FCF | -6.78 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -213.5% |
| ROI | -84.0% |
| ROIC | -63.8% |
| Profit margin | -341.5% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | 12,065.5% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 37 |
| Quality score | -88.2% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 160.005M | 154.014M | 200.521M | 128.304M | 130.513M | 78.893M | 90.891M | 78.626M | 93.468M | 90.714M | 92.782M | 60.594M | 28.181M | 25.983M | 33.863M | 1.674M |
| Net profit | -546.376M | -309.851M | -306.735M | -314.248M | -181.223M | 29.403M | -84.134M | -102.562M | -92.189M | -74.375M | -31.696M | -66.16M | -79.293M | -94.465M | -109.388M | -140.166M |
| Free cash flow | -113.923M | -212.246M | -268.016M | -279.961M | -117.111M | 18.464M | -81.148M | -68.284M | -77.951M | -76.136M | -50.898M | -53.077M | -30.742M | -78.525M | -112.258M | -127.255M |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 1.87 | 1.83 | 9.81 | 8.18 | 20.46 | 25.94 | 5.14 | 7.4 | 2.64 | 3.8 | 13.13 | 7.84 | 5.23 | 1.7 | 5.68 | — |
| Price performance 12m | 0.02 | -0.81 | 0.2 | -0.6 | -0.21 | 4.05 | -0.31 | 1.8 | -0.31 | -0.71 | 0.67 | 0.5 | 2.08 | -0.7 | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (USD) | 11.4M | 13.4M | 8.6M | 15.3M | 16.8M | 24.2M | 18.8M | 36.6M | 27.5M | 35.4M |
| ↳ YoY growth | +117.8% | +17.6% | -36.0% | +77.6% | +10.3% | +44.0% | -22.5% | +94.9% | -24.8% | +28.8% |
| ↳ 5y CAGR | +20.2% | +36.6% | +25.6% | +35.0% | +26.3% | +16.2% | +6.9% | +33.6% | +12.5% | +16.1% |
| Borrowings, current (USD) | — | — | — | — | — | 1.61M | 1.84M | 490,000 | 0.00 | — |
| Lease liabilities (USD) | — | — | 49.2M | 45.8M | 42M | 57.7M | 50M | 41.2M | 24.9M | 57M |
| Cash and deposits (USD) | 16.8M | 16.5M | 18.8M | 29.6M | 81.6M | 461M | 325M | 180M | 55.4M | 63.7M |
| Intangible assets (USD) | — | — | — | — | — | 411M | 410M | 457M | 390M | 15.1M |
| Right-of-use assets (USD) | — | — | 35.5M | 32.8M | 30M | 46.6M | 39.8M | 32.6M | 16.1M | 41.7M |
| Net debt (borrowings + leases - cash) (USD) | — | — | — | — | — | -401M | -273M | -138M | -30.4M | — |
| Cash flow detail | ||||||||||
| Operating cash flow (USD) | -67.9M | -67.5M | -66.4M | -78.3M | 19.5M | -111M | -263M | -259M | -206M | -111M |
| Purchases of property, plant and equipment (USD) | -8.21M | -10.4M | -1.85M | -2.84M | -1.04M | -5.93M | -16.8M | -8.84M | -6.19M | -2.71M |
| Purchases of intangible assets (USD) | — | — | — | — | — | 0.00 | -179,000 | 0.00 | 0.00 | -5M |
| Change in receivables (cash effect) (USD) | -6.18M | -2.01M | 4.84M | -6.67M | -1.6M | -7.17M | 5.46M | -17.8M | 9.09M | -7.92M |
| Change in inventories (cash effect) (USD) | -6.15M | -8.44M | 3.62M | 3.92M | -1.1M | -12.4M | -33.9M | -13.8M | -8.32M | -1.42M |
| Change in payables (cash effect) (USD) | 3.4M | 764,000 | -2.24M | 1.71M | -5.07M | 6.36M | 1.03M | 206,000 | 1.41M | 2.48M |
| Interest paid (cash effect) (USD) | -1.8M | -1.69M | -1.4M | -1.4M | -491,000 | -6.93M | -14M | -15.7M | -14.8M | -8.26M |
| Income taxes paid (cash effect) (USD) | — | — | — | — | — | — | — | -140,000 | -256,000 | -481,000 |
| Share-based compensation (USD) | 19.6M | 20.4M | 23.2M | 16.4M | 17.5M | 73.4M | 78.6M | 72.1M | 71M | 41.7M |
| Operating cash flow before change in receivables (USD) | -61.8M | -65.5M | -71.3M | -71.6M | 21.1M | -104M | -269M | -241M | -215M | -103M |
| Free cash flow (OCF - PPE - intangibles) (USD) | -76.1M | -78M | -68.3M | -81.1M | 18.5M | -117M | -280M | -268M | -212M | -119M |
| Income detail | ||||||||||
| Research and development expense (USD) | 67.6M | 65.3M | 62.6M | 59.6M | 64.2M | 113M | 193M | 187M | 135M | 97.3M |
| ↳ 5y CAGR | -2.3% | +6.5% | +6.7% | +4.3% | +1.2% | +10.8% | +24.2% | +24.5% | +17.7% | +8.7% |
| Total comprehensive income (USD) | -74.4M | -92.2M | -103M | -84.1M | 29.5M | -182M | -318M | -302M | -310M | -546M |
| Comprehensive income to owners (USD) | -74.4M | -92.2M | -103M | -84.1M | 29.5M | -182M | -318M | -302M | -310M | -546M |
| Reported | Mar 6, 2017 | Feb 26, 2018 | May 3, 2019 | Feb 28, 2020 | Feb 26, 2021 | Feb 28, 2024 | Feb 28, 2023 | Feb 25, 2026 | Feb 25, 2026 | Feb 25, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.

ASHG 2026 brought the human genetics community to Montréal this past October for a week of science spanning rare disease, cancer, population genomics, and new approaches to working with genomic data at scale. For the PacBio team, it was also a valuable chance to hear directly from researchers about the questions they are pursuing and where open questions remain.
Between packed session rooms and steady conversation on the exhibit floor, the meeting reflected how quickly the field is moving toward richer genomic data. Through an industry workshop, CoLab sessions, and posters, customers and collaborators shared how HiFi long-read sequencing is helping bring those layers into view in settings that range from population-scale programs to clinical research laboratories.
Many of these discussions returned to biology that has been difficult to reach with traditional methods. Structural variants, repeats, isoforms, and methylation patterns often hold the context behind unexplained findings, yet short-read data leave much of it unresolved. For a closer look at the types of variation short reads miss and how HiFi sequencing captures them, explore our new variant guide.
HiFi sequencing at scale
The industry workshop opened with a look at the growing momentum behind HiFi sequencing, as cumulative customer data output continues to climb each year with more laboratories gaining a more complete view of the genome and putting the technology to work. Updates across the workflow followed, including on-instrument detection of 5mC, 5hmC, and 6mA alongside the four DNA bases, faster analysis tools, and a rapid whole genome sequencing workflow also featured on the poster floor.
The session also introduced the new Nanobind HT plus kit for high-molecular-weight DNA extraction from blood, saliva, and buccal samples. The kit replaces the Nanobind disk with beads to improve DNA capture, particularly from lower-mass samples, while retaining the existing Nanobind buffers that preserve purity and DNA quality. The bead-based format is simpler to automate on the KingFisher Apex system, and extracted DNA can move directly into library preparation without overnight solubilization.
Interest in using HiFi data for AI was another theme, since accurate sequence, native methylation, and full-length transcripts give models consistent, multi-layered information to learn from. TychoBio is working with PacBio to build AI models for rare disease RNA therapies using Kinnex full-length RNA data, and as TychoBio founder and CEO, Felix Raimundo emphasized,
AI models are only as good as the data they are trained on. To effectively identify new rare disease treatments, we needed the highest quality biological data, which can only be generated using PacBio HiFi sequencing technology.
Basecamp Research has also selected HiFi sequencing for its trillion-gene atlas initiative, and a multi-year collaboration with Verily pairs HiFi data and phenotypic information with standardized analysis workflows in Verily’s Trusted Research Environment.
Customer presentations began with Jonathan Schultz of Sampled, who described how laboratory automation, SPRQ chemistry, and a scaled-out fleet of Revio systems came together to deliver 3,304 HiFi genomes for the Million Veteran Program, a U.S. Department of Veterans Affairs research program that has enrolled more than one million Veterans.
Sneha Mokashi and Adithya Kandhadai of Greenwood Genetic Center then described how a single validated long-read genome test on Revio now covers variant classes that previously required short-read WGS, repeat sizing assays, targeted Sanger sequencing, and optical genome mapping. Examples included a PLIN4 repeat expansion identified after an uninformative short-read genome.
Fabio Cunial of the Broad Institute closed the workshop with structural variant integration for the All of Us Research Program, which now spans more than 12,000 samples from four sequencing centers. To keep small numbers of false calls from accumulating across the cohort, Cunial’s team combined multiple callers, machine learning filters, and a graph-based genotyper, producing a callset of about 2.5 million structural variants of 50 bp or larger for roughly $0.10 to $0.20 per sample.
Episignatures from native methylation
Moving to the CoLab sessions, the first asked how methylation can help turn uncertain rare disease findings into meaningful answers. Episignatures, the reproducible DNA methylation patterns shared by individuals with the same disorder, can offer functional evidence to help interpret variants of uncertain significance.
Sanaa Choufani of The Hospital for Sick Children reported that in a pilot of 47 samples, episignature classification using HiFi methylation data was fully concordant with array results. Because HiFi reads measure methylation genome-wide rather than at preselected probes, her team identified 22 differentially methylated positions associated with NSD1 variants, compared with three captured by the array. In one research case with negative exome and genome results, HiFi data confirmed the expected methylation signature and uncovered a deep intronic variant within the same assay.
Christian Gilissen of Radboud University Medical Center shared haplotype-resolved methylation at 24 of 25 imprinted regions and a workflow that applies published episignatures to HiFi data against a reference cohort of more than 4,300 Revio genomes.
Long-read whole genome sequencing for clinical research
The second CoLab considered how complete a whole genome really is, and whether a single, more comprehensive test could shorten the path to answers in clinical research. The session opened with recent publications evaluating HiFi WGS on real-world samples. In one study of 191 rare disease research samples, HiFi WGS detected 99.6% of 481 known pathogenic variants, and work from Children’s Mercy Kansas City reported a mean turnaround of 27 days compared with 62 days for standard testing.
Michael Kahl of Lurie Children’s Hospital of Chicago then shared results from a research study of families who remained unsolved after conventional testing. Among 29 families, long-read genome sequencing identified additional findings in roughly 28%, including a 6.47 Mb inversion disrupting NSD1 that short-read exome sequencing had not detected and a frameshift deletion within the highly repetitive TTN I-band region. His team also showed that Fragile X repeat sizing and Prader-Willi and Angelman methylation profiles can be assessed from the same genome.
Consolidating repeat expansion testing
The final CoLab explored whether complex targeted testing, particularly for repeat expansions and genes with close pseudogenes, can be brought together in one workflow. Laura Glaser of MGZ Medical Genetics Center in Munich described how her lab previously relied on fragment analysis, Sanger sequencing, and multiple nanopore panels to cover repeat expansion targets. By adopting PureTarget, which uses PCR-free enrichment to sequence many repeat loci in a single multiplexed run, her team validated one repeat expansion workflow across 25 loci. She also shared practical lessons, including the importance of DNA quality and of adjusting coverage expectations for longer expanded alleles.
Highlights from the poster sessions
Six PacBio posters extended these themes, introducing new tools and workflows across epigenetics, repeats, transcriptomics, and sample preparation.
Simultaneous genetic and epigenetic profiling. HiFi 5mC calls showed strong agreement with whole-genome bisulfite sequencing, supporting genetic and epigenetic analysis from a single dataset. The poster also covered 6mA detection for EpiCypher’s Fiber-seq assay, which enables joint profiling of CpG methylation and chromatin accessibility on individual DNA molecules, providing a high-resolution view of the genome sequence and epigenetic landscape.
Methylation in multiple myeloma. Using the MethBat toolkit, this study detected both genome-wide hypomethylation and localized hypermethylation of CpG islands in multiple myeloma cell lines, showing how one long-read dataset can recover known tumor epigenetic signals alongside genetic variants.
Resolving D4Z4 in FSHD. With the Kivvi tool, PacBio and collaborators at GeneDx and Leiden University Medical Center characterized the D4Z4 repeat associated with FSHD across 601 individuals from five ancestral populations, moving closer to consolidating multiple FSHD assays into a single sequencing workflow. Learn more in the FSHD blog.
Rapid HiFi WGS. Developed with GeneDx, an accelerated workflow goes from blood to VCF in under 30 hours and detects previously characterized variants in 29 of 31 samples, bringing comprehensive long-read variant detection into a timeframe suited to time-critical research. Read more about rapid HiFi whole genome sequencing or explore the rapid WGS resource bundle.
Full-length RNA at cohort scale. Isocall enables joint isoform calling across hundreds of samples, supported by new workflows for Kinnex full-length RNA data, making population-scale studies of transcript diversity more practical.
One-hour HMW DNA extraction. Automated extraction with the Nanobind HT plus kit recovered high-quality DNA from blood and saliva across 308 samples with consistent HiFi WGS and PureTarget performance, helping large studies work with non-invasive sample types without compromising long-read data quality.
Completing the genomic picture
Across talks and posters, a common thread emerged. Population programs building structural variant resources, laboratories interpreting variants of uncertain significance, and teams consolidating targeted assays all pointed toward the same need for data that capture more of the genome’s structure and regulation the first time. A genome is not finished if the biology researchers need is still unresolved, and structural variation, isoforms, and methylation each add context that short reads cannot adequately provide.
The work shared in Montréal also showed how much of that context is already within reach. Laboratories are validating long-read tests, large programs are scaling HiFi to thousands of genomes, and new tools are making methylation, repeats, and full-length transcripts easier to analyze alongside sequence.
For teams considering where long reads could help first, our new variant guide explores the variation short reads miss and the published studies behind it.
Subscribe for blog updates:
-
Filter by topic
Talk with an expert
If you have a question, need to check the status of an order, or are interested in purchasing an instrument, we're here to help.
Contact America Sales
Contact EMEA Sales
Contact APAC Sales
General inquiries
November 4, 2026 at 4:05 PM EST
MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2026.
Recent Business Highlights
-
Delivered total revenue of $40.6 million, reflecting continued instrument and consumables demand
-
SPRQ-Nx adoption built through the quarter, with over half of Revio consumables revenue tied to SPRQ-Nx and two-thirds of the Revio installed base opting to upgrade software for use of SPRQ-Nx by the end of the quarter
-
Delivered 35 new Vega systems in the quarter, up 9% year-over-year, with more than 90% sold to new customers, and launched SPRQ-Nx for Vega in late August
-
Partnered with GeneDx to add long-read whole genome sequencing capabilities to its genome testing portfolio. The move is expected to deepen PacBio’s role in rare disease and support PacBio's priority to grow clinical work
-
Strengthened PacBio’s presence in APAC through Berry Genomics’ Birth Defects Project, a major genomics study in China. The project is expected to put HiFi genome sequencing at the center of large-scale research in the region
-
Expanded HiFi’s reach into large-scale population research – the Department of Veterans Affairs awarded Sampled, a high-utilization Revio customer, a five-year contract to provide genomics analyses using long-read whole genome sequencing for the Million Veteran Program
-
Initiated a multi-year strategic collaboration with Verily Health to combine HiFi long-read data with real-world clinical data at population scale. The datasets are expected to support discovery and AI model training on Verily’s Workbench platform, which serves more than 20,000 researchers, putting HiFi data in front of a large research community
-
Announced collaboration with TychoBio, an AI drug discovery company, to generate full-length RNA datasets with HiFi and Kinnex sequencing. We expect the data will be used to train AI models to predict RNA therapy efficacy and off-target effects, extending PacBio’s rare disease role toward therapy development
-
Jim Gibson has stepped down as Chief Financial Officer (CFO). Mark Van Oene has been appointed interim CFO and Bill Meyer has been appointed Chief Accounting Officer (CAO) as PacBio engages in a search for a new CFO
“PacBio is entering an exciting phase as the investments we’ve made in our technology begin to unlock new opportunities,” said Mark Van Oene, President and Chief Executive Officer. “SPRQ-Nx is changing the economics of HiFi sequencing, while growing clinical adoption and strategic collaborations in population genomics and AI are expanding the markets we can serve. We have a tremendous opportunity ahead of us, and my focus is clear: sharpen our execution, prioritize what matters most, and translate the strength of our technology into sustainable growth.”
Third quarter****results:
| | Q3 2026 | | Q3 2025 |
| Revenue(in millions) | $40.6 | | $38.4 |
| Consumable revenue(in millions) | $20.8 | | $21.3 |
| Instrument revenue(in millions) | $13.2 | | $11.3 |
| Service and other revenue(in millions) | $6.6 | | $5.8 |
| Revio™ system placements | 15 | | 13 |
| Vega™ system placements | 35 | | 32 |
| Annualized Revio pull-through per system | ~$204,000 | | ~$236,000 |
| Ending cash, cash equivalents, and investments(in millions) | $199.4 | | $298.7 |
Gross profit and margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the corresponding GAAP measures at the end of this release.
GAAP gross profit for the third quarter of 2026 was $13.5 million compared to $15.9 million during the third quarter of 2025. Non-GAAP gross profit for the third quarter of 2026 was $14.6 million compared to $16.2 million for the third quarter of 2025. GAAP gross margin was 33% for the third quarter of 2026 compared to 41% for the third quarter of 2025. Non-GAAP gross margin was 36% for the third quarter of 2026 compared to 42% for the third quarter of 2025. The decline in non-GAAP gross margin was primarily driven by higher memory costs and Vega manufacturing transition costs.
GAAP operating expenses totaled $50.5 million for the third quarter of 2026 compared to $54.8 million for the third quarter of 2025. Non-GAAP operating expenses totaled $47.0 million for the third quarter of 2026 compared to $53.9 million for the third quarter of 2025. The decrease in GAAP and non-GAAP operating expenses primarily reflects lower personnel and related expenses, resulting from PacBio’s restructuring initiatives. GAAP and non-GAAP operating expenses for the third quarter of 2026 and the third quarter of 2025 included non-cash share-based compensation of $8.0 million and $10.1 million, respectively.
GAAP net loss for the third quarter of 2026 was $37.8 million compared to $38.0 million for the third quarter of 2025. Non-GAAP net loss for the third quarter of 2026 was $32.8 million compared to $36.8 million for the third quarter of 2025.
GAAP net loss per share for the third quarter of 2026 was $0.12 compared to $0.13 for the third quarter of 2025. Non-GAAP net loss per share for the third quarter of 2026 was $0.11 compared to $0.12 for the third quarter of 2025.
2026 Financial Outlook
PacBio now expects revenue for the full year 2026 to be in the range of $155 million to $160 million.
Quarterly Conference Call Information
Management will host a quarterly conference call today at 4:30 p.m. Eastern Time to review financial results for the third quarter ended September 30, 2026. Investors can access the call by dialing 1-888-349-0136 (or 1-412-317-0459 for international callers) and requesting to join the “PacBio Q3 Earnings Call". The call will be webcast live and available for replay at PacBio's website at https://investor.pacificbiosciences.com.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which consist of our HiFi long-read sequencing systems, address solutions across a broad set of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Statement Regarding Use of Non‐GAAP Financial Measures
PacBio reports non‐GAAP results for basic net income (loss) per share, net income (loss), gross margins, gross profit (loss) and operating expenses in addition to, and not as a substitute for, or because it believes that such information is superior to, financial measures calculated in accordance with GAAP. PacBio believes that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of PacBio’s non-GAAP financial measures as tools for comparison. For future periods PacBio is unable to reconcile non-GAAP gross margin and non-GAAP operating expenses without unreasonable effort because certain items that impact these measures are out of PacBio’s control or cannot be reasonably predicted at this time, and their probable significance cannot be determined.
PacBio's financial measures under GAAP include substantial charges that are listed in the itemized reconciliations between GAAP and non‐GAAP financial measures included in this press release. PacBio excludes recurring charges from its non-GAAP financial statements, including amortization of acquired intangible assets, amortization of a patent license, interest expense related to the liability incurred in connection with the PGI settlement, and changes in fair value of contingent consideration, and further excludes infrequent and limited charges including impairment charges, restructuring-related expenses for discrete restructuring events, settlement charges, disposition of short-read assets, benefits from income taxes and other adjustments and rounding differences.
Management has excluded the effects of these items in non‐GAAP measures to assist investors in analyzing and assessing past and future operating performance. In addition, management uses non-GAAP measures to compare PacBio’s performance relative to forecasts and strategic plans and to benchmark its performance externally against competitors.
PacBio encourages investors to carefully consider its results under GAAP, as well as its supplemental non‐GAAP information and the reconciliation between these presentations, to more fully understand its business. A reconciliation of PacBio’s non-GAAP financial measures to their most directly comparable financial measure stated in accordance with GAAP has been provided in the financial statement tables included in this press release.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, statements relating to PacBio’s initiatives as well as the expected financial impact and timing of these plans and initiatives, including PacBio's expectations regarding long-read sequencing and SPRQ-Nx; PacBio's expectations regarding its restructuring efforts; PacBio’s financial guidance and expectations for future periods; the expected benefits of PacBio’s collaborations and customer programs, including with TychoBio and Verily Health; new and continued reception of PacBio’s products and their expansion into new or existing markets; and the availability, uses, accuracy, coverage, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies. Reported results and orders for any instrument system should not be considered an indication of future performance. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, but not limited to, challenges inherent in developing, manufacturing, launching, marketing and selling new products, and achieving anticipated new sales; PacBio’s ability to realize the anticipated benefits of its collaborations; potential cancellation of existing instrument orders; assumptions, risks and uncertainties related to the ability to attract new customers and retain and grow sales from existing customers; risks related to PacBio's ability to successfully execute and realize the benefits of acquisitions; the impact of new, increased or enhanced tariffs and export restrictions; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in costs or expenses; high costs of computer memory components; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; potential product performance and quality issues and potential delays in development timelines; the possible loss of key employees, customers, or suppliers; customers and prospective customers curtailing or suspending activities using PacBio's products; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; risks associated with international operations; and other risks associated with general macroeconomic conditions and global economic or political instability, including war and other international conflicts, such as the conflicts in the Middle East. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
The unaudited condensed consolidated financial statements that follow should be read in conjunction with the notes set forth in PacBio's Quarterly Report on Form 10-Q when filed with the Securities and Exchange Commission.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Pacific Biosciences of California, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| ARKG | 1.25% | 12,542,409 | $ 22.827M | Nov 18, 2026 |
| EVNT | 0.64% | 62,000 | $ 84.01K | Aug 31, 2026 |
| ARKK | 0.40% | 27,662,849 | $ 50.346M | Nov 18, 2026 |
| NXTE | 0.29% | 98,761 | $ 165.918K | Jun 30, 2026 |
| ORR short | -0.14% | -287,285 | $ -520K | Nov 18, 2026 |
| MEDX | 0.09% | 10,068 | $ 16.914K | Jun 30, 2026 |
| RESM | 0.02% | 491 | $ 824.88 | Jun 30, 2026 |
| DFAS | 0.00% | 10,460 | $ 20.606K | Nov 12, 2026 |
| DFAC | 0.00% | 16,848 | $ 33.191K | Nov 12, 2026 |
| DFUS | 0.00% | 2,988 | $ 5,886.36 | Nov 12, 2026 |
| DCOR | 0.00% | 451 | $ 888.47 | Nov 12, 2026 |



